NYU Conference on Ibogaine Nov 5-6, 1999

Search the Web!

Neurotoxicity

Introduction

1. A Dose-Response Study of Ibogaine-Induced Neuropathology in the Rat Cerelellum. Xu Z., Chang L.W., Slikker W. Jr., Ali S.F., Rountee R.L., Scallet A.C. Toxicol Sci 57(1):95-101,2000.
2. Effects of Chronic Ibogaine Treatment on Cerebellar Purkinje Cells in the Rat. Helsley, S., Dlugos C.A., Pentney R.J., Rabin R.A., Winter J.C. Brain Reseach 759(2):306-308, 1997.
3. Ibogaine neurotoxicity: a re-evaluation. Molinari, H.H., Maisonneuve, I.M. and Glick, S.D. Brain Res 737:255-262, 1996.
4. 18 Methoxycoronaridine, a Nontoxic Iboga Alkaloid Congener: Effects on Morphine and Cocaine Self Administration and on Mesolimbic Dopamine Release in Rats. Glick, S.D., Kuehne, M.E., Maisonneuve, I.M., Bandarage, U.K. and Molinari, H.H. Brain Res 719:29-35, 1996.
5. NMDA Antagonist Properties of the Putative Antiaddictive Drug, Ibogaine. Popik, P., Layer, R.T., Fossom, L.H., et al. J Pharmacol Exp Ther 275:753-760, 1995.
6. Ibogaine research update: phase I human study. Sanchez-Ramos, J. and Mash, D.C. Multidisciplinary Association for Psychedelic Studies 4:11, 1994.
7. Ibogaine induces glial activation in parasagittal zones of the cerebellum. O'Hearn, E., Long, D.B. and Molliver, M.E. Neuroreport 4:299-302, 1993.
8. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. O'Hearn, E. and Molliver, M.E. Neuroscience 55:303-310, 1993.